Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

@article{Volberding1990ZidovudineIA,
  title={Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.},
  author={Paul A. Volberding and Stephen W Lagakos and Matthew A. Koch and Carla Pettinelli and Maureen W Myers and David J. Booth and Henry H. Balfour and Richard C Reichman and John A. Bartlett and Martin S. Hirsch},
  journal={The New England journal of medicine},
  year={1990},
  volume={322 14},
  pages={941-9}
}
Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or… CONTINUE READING
173 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 173 extracted citations

Similar Papers

Loading similar papers…